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Abstract
Background—Little is known about how the prevalence and incidence of neurological disease
in HIV-infected patients in resource-limited settings. We present an analysis of neurological and
neurocognitive function in antiretroviral naïve individuals in multinational resource-limited
settings.
Methods—This prospective multinational cohort study, a substudy of a large international
randomized antiretroviral treatment trial, was conducted in 7 low and middle income countries in
Sub-Saharan Africa, South America, and Asia. Subjects were HIV-infected and met regional
criteria to initiate antiretroviral therapy. Standardized neurological examination and a brief motor-
based neuropsychological examination were administered.
Results—860 subjects were studied. Overall 249 (29%) had one or more abnormalities on
neurological examinations, but there was a low prevalence of HIV-associated dementia (HAD)
and minor neurocognitive disorder (MND). Twenty percent of subjects had evidence of peripheral
neuropathy. There were significant differences across countries (p<.001) in neuropsychological
test performance.
Conclusions—In this first multinational study of neurological function in antiretroviral naïve
individuals in resource-limited settings, there was a substantial prevalence of peripheral
neuropathy and low prevalence of dementia and other CNS diseases. There was significant
variation in neurocognitive test performance and neurological examination findings across
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countries. These may reflect cultural differences, differences in HIV-related and unrelated
diseases, and variations in test administration across sites. Longitudinal follow-up after
antiretroviral treatment initiation may help to define more broadly the role of HIV in these
differences as well as the impact of treatment on performance.
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Introduction
The burden of the human immunodeficiency virus type 1 (HIV-1) epidemic is staggering,
particularly in resource-poor, developing parts of the world where 95 percent of new
infections occur (World Health Organization 2003). Since the early years of the HIV-1
epidemic in the developed world, it has been recognized that the central and peripheral
nervous systems (CNS and PNS) are impacted in HIV-1 infection, both by opportunistic
infections and by conditions that relate to the virus, itself. Though the precise mechanisms
are uncertain, there is considerable evidence to suggest that the local effects of viral and
immune factors in the CNS and PNS underlie this neurotoxicity (Price and Spudich 2008).
The spectrum of HIV-related CNS diseases has recently been given the name HIV-
Associated Neurological Disorders (HAND) (Antinori et al. 2007). This includes not only
the more severe form of HIV-associated dementia (HAD), but also less severe nervous
system dysfunction, termed HIV-associated minor neurocognitive disorder (MND), that is
detected in a larger portion of infected patients. These disorders were previously known as
acquired immunodeficiency syndrome (AIDS) Dementia Complex and minor cognitive/
motor disorder respectively (Navia et al. 1986; Navia et al. 1986; American Academy of
Neurology 1991; Robertson and Hall 1992; McArthur et al. 1993). In the era prior to highly
active antiretroviral therapy (HAART), as many as 80% of people who died from AIDS in
the United States had autopsy evidence of CNS injury attributable to HIV-1 regardless of
whether there had been clear manifestations of HAD during life (Elder and Sever 1988).
Likewise, the PNS is commonly affected in HIV-1 infection, and while a variety of different
neuropathies have been described, the predominant type is a distal primary sensory
polyneuropathy (DSPN) that is often associated with severe pain and reduction in quality of
life. DSPN has been reported to have a prevalence of up to 60% in advanced HIV-1 disease
(Simpson et al. 2006). A complicating factor is that the deoxynucleotide antiretroviral drugs,
including, didanosine, zalcitabine, and stavudine may cause a neuropathy that is clinically
indistinguishable from DSPN (Sacktor 2002; Schifitto et al. 2005).
The burden of neurological disease on families and communities is substantial, with loss of
productivity and income for the diagnosed and for those who take the primary responsibility
as caretakers. In resource-limited settings with high rates of HIV-1 infection the toll is likely
devastating, but remains to be documented (Schifitto et al. 2001; Tozzi et al. 2004). In the
developed world, cognitive impairment is relatively common in HIV-infected individuals
who have not been treated with antiretroviral therapy (McArthur et al. 1993). Little is known
about the prevalence of HAD, milder neuropsychological dysfunction and peripheral
neuropathy in HIV-1 infected people in resource-limited settings who have not received
ART. The overall purpose of our study was to conduct neurological and neuropsychological
assessments in treatment-naïve HIV-1-infected individuals in order to determine HAND and
peripheral neuropathy prevalence in those initiating treatment, and, eventually, the impact of
different regimens on these conditions. We report here the baseline pre-antiretroviral
treatment results from ACTG 5199.
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A5199 was an AIDS Clinical Trials Group (ACTG) study that was organized as a substudy
of ACTG A5175, a randomized trial that focused on treatment strategies and systemic
disease outcomes. The international ACTG sites that participated in the study were located
in Rio de Janeiro, Brazil; Porto Alegre, Brazil; Chennai, India; Pune, India; Blantyre,
Malawi; Lilongwe, Malawi; Lima, Peru; Johannesburg, South Africa; Durban, South Africa;
Chiang Mai, Thailand; and Harare, Zimbabwe.
Procedures
Human subjects study review and approval by local and country specific review boards were
obtained at each site prior to study initiation. The National Institutes for Health (NIH),
National Institute for Allergy and Infectious Diseases (NIAID), Division of AIDS (DAIDS),
and Multinational Data Safety and Monitoring Board monitored the study at intervals to
ensure safe and appropriate conduct. Each international site was required to enroll 10
participants successfully in the parent study (ACTG A5175), pass a quality assurance visit,
and then enroll another 10 participants successfully in A5175 before the sites were allowed
to start enrollment unencumbered. This ensured that the study infrastructure was working
appropriately and assured quality data collection. Once the neurological and
neuropsychological exams were finalized, case report forms were developed with
appropriate skip logic. Sites then translated the forms into local languages and back
translated, with discrepancies resolved. Standardized training on administration of the
neurological and neuropsychological examinations was conducted on site. Centralized
training occurred on a biannual basis at A5199 team meetings. Sites were also provided with
web-based and DVD training modules. Computerized data entry screens were implemented
at the sites with infrastructure support. Rigorous data monitoring at data entry through
computerized range checks, with follow-up data cleaning through multiple queries and
replies were conducted throughout the study. Implausible values were queried and
confirmed or corrected at intervals.
Participants
Participants were a subset of relatively healthy, HIV-1 seropositive, antiretroviral naïve
individuals with CD4+ cell counts less than 300 cells/mm3 who planned to enroll in ACTG
A5175, a randomized antiretroviral treatment trial. Eligible subjects were men and women
18 years or older who had documented HIV-1 infection, CD4+ lymphocytes less than 300
cells/ mm-3, Karnofsky performance score greater than or equal to 70, and no more than
seven days of cumulative prior antiretroviral therapy prior to study entry. Women of
reproductive potential could not be pregnant and, if participating in sexual activity that could
lead to pregnancy, had to agree to the use of contraception. Persons with serious chronic,
acute, or recurrent infections must have completed at least 14 days of therapy or be
clinically stable. Exclusionary criteria included absolute neutrophil count less than 750 cells/
mm-3, hemoglobin less than 7.5 g/dL, platelet count less than 50,000 mm-3, calculated
creatinine clearance less than 60 mL/min, aspartate transaminase (AST) alanine
transaminase (ALT) or alkaline phosphatase greater than 5-fold above the upper limit or
normal, total bilirubin greater than 2.5-fold above the upper limit of normal, clinical
pancreatitis within 3 years, bradycardia (<40 min-1) or a history of untreated active 2nd or
3rd degree heart block. In addition, participants were also excluded from participation in the
study if they had any active severe psychiatric illness, active drug or alcohol abuse or
dependence, serious illness and/or hospitalization, or any other condition that, in the opinion
of the site investigator, would compromise the person's ability to participate in the study,
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adhere to study requirements, or confound the analysis or interpretation of the results of the
study.
Neurological and neuropsychological examinations
The A5199 neurological examination was initially developed and field-tested at selected
sites. Revisions to content and length were made, eliminating confusing or culturally
inappropriate items, and the examination field-tested again. The examination included a
neurological history and symptom review and brief cognitive, motor, sensory and reflex
assessments. Based on examination results, a neurologic diagnosis was assigned. Using the
results from the neurological history and exam, the evaluator then made a judgment as to
whether the neurological examination was normal or abnormal. If abnormal, the evaluator
assessed the degree of abnormality and whether it appeared due to diffuse or focal central
nervous system (CNS) disease, peripheral nervous system (PNS) disease or a combination.
Neuropsychological assessment is sensitive and specific for HIV-1-related cognitive
dysfunction (Price and Sidtis 1990; Sidtis et al. 1993). The neuropsychological test battery
was chosen based on prior experience in clinical trial and cohort studies in the United States,
with particular care taken to keep the battery short and minimizing language- and cultural-
specific items. The tests administered were Timed Gait, Grooved Pegboard (dominant and
nondominant hands), Finger Tapping (dominant and nondominant hands), and Semantic
Verbal Fluency. The neuropsychological tests were not used for assigning impairment
ratings or for diagnoses of HAND in this study, as appropriate normative data does not exist
to make these comparisons. Each patient was used as their own control, and comparison of
the neuropsychological treatment response over time was the main outcome.
A study-specific diagnosis form was completed for each participant and included HIV-
associated dementia, mild cognitive motor disorder and peripheral neuropathy, in addition to
CNS opportunistic infections. In absence of appropriate normative data for the
neuropsychological tests, the neurological exam summary assessment of diffuse CNS
disease related to HIV of subclinical/equivocal was use coded for MND, and the mild,
moderate or severe ratings were coded as HAD.
Results
Demographics
The total enrollment was 860 participants: 452 (53%) females and 408 (47%) males. The
median age was 34 years, and the median educational level was 10 years (Q1-7, Q3-12).
Few participants (13/860; 1.5%) had a history of intravenous (IV) substance abuse. The
A5199 cohort was representative of the A5175 cohort at sites that were enrolling subjects
into A5199. Table 1 presents screening CD4+ cell counts and entry HIV RNA by country.
Neurological evaluation
Overall, 249 (29%, 95% CI) of subjects had an abnormal neurological examination and the
number of participants with any neurological abnormality assessment varied from 8% in
Peru to 74% in Thailand (Table 2, p<0.001). The most common neurological diagnosis was
peripheral neuropathy, diagnosed in 178 (20%, 95% CI) of subjects (Table 2). As with the
other neurological diagnoses identified in this study, most neuropathy diagnoses were
categorized as subclinical or mild in severity.
Only 4 participants were diagnosed with HAD (Table 3). Mild neurocognitive disorder
(MND) was diagnosed in 6% of the participants with 95% CI (4.4%, 7.7%), ranging from
0% in Thailand to 14% in Zimbabwe. Substantial country variation was noted with respect
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to overall neurological assessment. The percentage of participants with a normal overall
neurological assessment ranged from 26% in Thailand to 92% in Peru (Table 2).
Examination of the components revealed country variation in all neurological diagnoses
(ranging from 1% in Malawi to 74% in Thailand) and peripheral neuropathy (ranging from
2% in India to 70% in Thailand) although most disease was scored as ‘equivocal/
subclinical.’ Significant variations in the frequency of HAD (p =0.014) and MND (p<0.001)
between countries were noted. There was no significant variation on the neurological exam
across HIV RNA strata (<100,000 and >100,000 cp/ml). There was a significant increase in
abnormality in the overall neurologic assessment (p=0.009), and HAD (p =0.014) as CD4+
cell counts decreased across strata (<50, 50-99, 100-199, 200-249, and 250-299 cells/mm3).
There was no association with plasma HIV RNA level.
At baseline, as shown in Table 4, 27 (3.1%) subjects were diagnosed with peripheral
neuropathy, 13 (1.5%) with extra-pulmonary tuberculosis, 37 (4.3%) with pulmonary
tuberculosis, 8 (0.9%) with varicella zoster, and 11 (1.3%) with depression. Few other
diagnoses were noted. Considerable country variation was noted with respect to these
diagnoses. Among the 11 subjects with depression, 3 were from Brazil, 1 from India, 5 from
South Africa, and 2 from Thailand.
Neuropsychological test results
The neuropsychological test baseline results are presented in Table 5. There were no
significant differences in neuropsychological test performance between subjects in the two
plasma HIV RNA strata noted above. Timed Gait had a mean of 12. 9 seconds (SD 2.4).
Grooved Pegboard dominant hand had a mean 81.9 seconds (SD 28.1); the nondominant had
a mean of 90.5 seconds (SD 29.6). Semantic Verbal Fluency had a mean of 16.2 words (SD
5.9). Fingertapping dominant had a mean of 38.3 taps (11.9); fingertapping nondominant
had a mean of 35.7 taps (SD 10.4). Likewise, there were no differences in test performance
in the CD4 strata (see above) except for better semantic verbal fluency scores with increased
peripheral blood CD4 cell counts (p= 0.027). Given the number of comparisons, these
results should be interpreted cautiously.
There were significant differences between countries as expected. For grooved pegboard
dominant and nondominant, Malawi and Zimbabwe had slower times relative to Thailand
and Peru. Similarly, the number of words recorded for semantic verbal fluency were greater
for Thailand and Peru, and relatively lower for Malawi, Zimbabwe and India. South Africa,
Thailand, and Peru had relatively faster timed gait scores than Malawi and Brazil.
Fingertapping dominant and nondominant scores were lower in Malawi and Peru, relative to
Zimbabwe and Thailand.
There were no significant relationships between plasma HIV RNA concentrations and CD4+
cell counts and performance on any of the neuropsychological tests. Compared to subjects
without HAD and MND, those given a diagnosis of HAD or MND had significantly poorer
performance on grooved pegboard dominant (p<.001), grooved pegboard non-dominant (p<.
001), semantic verbal fluency (p<.001), timed gait (p<.001), fingertapping dominant (p<.05)
and finger-tapping non-dominant (p<.005). These associations support the accuracy of the
clinical diagnoses that were made without considering the neuropsychological test scores.
Discussion
The prevalence of neurological and cognitive impairment in HIV-infected individuals in the
developing world has not been clearly delineated. While several studies have documented
substantial prevalence of peripheral neuropathy in resource-limited settings, ranging from
11-34%, particularly among patients who had received stavudine (Grey and Berger 2007;
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Affandi et al. 2008; Kumarasamy et al. 2008; Wright et al. 2008), reports of the prevalence
of cognitive impairment are more variable. The prevalence of HAD in sub-Saharan Africa
has been reported to be as low as 3% (Belec et al. 1989) to as high as 54% (Howlett et al.
1989). The largest study of HIV-associated neurological and cognitive impairment was
performed by the World Health Organization (Maj et al. 1994). Six hundred two HIV-
infected and 353 HIV-uninfected individuals were studied in Bangkok, Thailand; Kinshasa,
Zaire; Nairobi, Kenya; and São Paolo, Brazil. Substantial rates of neurological impairment
were identified in symptomatic individuals (41% Zaire, 40% Kenya, 66% Thailand, and
54% Brazil) (Maj et al. 1994). Similarly, Sacktor et al. (Sacktor et al. 2009) reported an
approximate 30% prevalence of HAD in Uganda, and Wright and colleagues identified
significant cognitive impairment in 11% of HIV-infected patients seen in ten different Asian
Pacific sites. In contrast, neurocognitive impairment was rare in studies of HIV-infected
individuals in Nairobi, Kenya, and in Zimbabwe (Parry et al. 1997; Mielke 2005; Jowi et al.
2007).
We assessed neurological and neuropsychological function in a large sample of ARV naïve
HIV-infected persons in resource limited settings. We found a substantial prevalence of
peripheral neuropathy (∼20%), but somewhat unexpectedly, only 6% of participants were
diagnosed with cognitive impairment. The severity of the diagnoses of peripheral
neuropathy and HAD or MND was rated as subclinical or equivocal in most cases.
Participants in this study were a subset of those enrolled in a larger study that examined
treatment response to three different ARV regiments. We may have underestimated the
prevalence and severity of neurological disease due to a selection bias. Specifically, a
Karnofsky score of 70 or better was an inclusion criterion, thus selecting for individuals who
were less likely to have neurological abnormalities. In addition, sites were encouraged to
recruit subjects who they thought would be compliant and adhere to study procedures,
potentially leading to a bias toward enrolling a healthier study population with less
neurological impairment.
The neurological assessments and diagnoses varied considerably by country, with
participants in Peru showing the lowest rates of neurological dysfunction (8%), diffuse CNS
dysfunction (2%), focal CNS dysfunction (3%) and peripheral neuropathy (5%). The
Zimbabwean cohort had the highest degree of overall neurological dysfunction (46%),
diffuse CNS dysfunction (17%), focal CNS dysfunction (11%) and peripheral neuropathy
(39%). This variation may simply have been due to differences in study populations.
Although differences in administration of the neurological examination may have also
played a role, care was taken to ensure that all study staff were appropriately trained to
accurately perform the neurological examination.
The variation in neuropsychological test results between countries that we observed in this
study was anticipated and has been seen in other studies. For example, in the World Health
Organization (WHO) (Maj et al. 1994) study, results of the timed gait test were abnormal in
29% of symptomatic HIV-infected participants in Zaire, 22% in Kenya, 58% in Thailand,
and 15% in Brazil. Such differences could be attributed to differences in study populations,
languages, cultures, or demographic factors. One important factor in our study was
differences in education across sites. For example, the median years of education ranged
from 8 in Malawi to 12.5 in Peru. The results from Malawi were relatively lower, while Peru
was relatively higher on a number of the tests, which may reflect educational level. As with
the neurological examination, differences in test scores between sites could be due to
variation in test administration. We minimized this possibility by on-site and central training
sessions.
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Different HIV subtypes likely predominated in the individual countries in which this study
was conducted, and those differences may have contributed to the differences in
neurological or neuropsychological performance that we observed. For example, Sacktor et
al. (2009) documented that among a group of HIV-infected individuals in Uganda, those
infected with subtype D had a greater prevalence of HIV associated neurological disease
than those with subtype A. Clade was not formally assessed in this study, and remains to be
determined. We found relatively poorer performance in Malawi, Zimbabwe, and India
which are thought to be predominantly clade C countries, although this pattern did not hold
in all countries thought to be predominantly clade C (South Africa). Relatively better
performance was found in Peru and Thailand, thought to be predominantly clade B andr A/E
respectively. This remains speculative at best until clade/subtype can be determined.
In the developed world, several studies show that initiation of HAART is associated with
improvement in cognitive and peripheral nervous system function (Gendleman et al. 1998;
Sacktor et al. 2002; McArthur et al. 2003; Robertson et al. 2004). We do not know whether
these neurological benefits will be seen in HIV-infected patients in resource-limited settings
who are treated with antiretrovirals. For example, while there is also evidence of a reduction
in peripheral nervous system disease in the HAART era in the developed world, use of
certain antiretroviral medications, particularly, stavudine, which is a common component of
first line ARV regimens in resource-limited settings, may result in a neuropathy which is
clinically indistinguishable from DSPN (Sacktor 2002; Schifitto et al. 2005).
HIV-associated cognitive impairment is associated with substantial impact on even the
simplest activities of daily living and even minor decline may be relevant, as the burden of
neurological disease on families and communities is substantial, with both an impact in
terms of loss of productivity and income for the diagnosed, but also for those who take the
primary responsibility as caretakers. In resource-limited settings with high rates of HIV-
infection, the toll is likely devastating, but remains to be documented (Schifitto et al. 2001;
Tozzi et al. 2004). The baseline results from this study document the current neurological
and neuropsychological status in this unique treatment naïve group. Future longitudinal
studies are required to address potential neurological benefits and harms of HAART in HIV-
infected patients in resource-limited settings.
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